Premium
P4‐383: Characterization of the Screened Population for the Tommorrow Study: a Pharmacogenetics‐Supported Clinical Trial to Delay the Onset of Mild Cognitive Impairment Due to Alzheimer’S Disease
Author(s) -
Martenyi Ferenc,
Welsh-Bohmer Kathleen A.,
Plassman Brenda L.,
Harrigan Patrick,
Chiang Carl,
O'Neil Janet,
Runyan Grant,
Culp Meredith,
Lutz Michael W.,
Lai Eric,
Saunders Ann M.,
Haneline Stephen,
Yarnall David,
Yarbrough Deborah,
Metz Craig,
Burns Daniel K.,
Roses Allen D.
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.07.129
Subject(s) - medicine , asymptomatic , population , disease , placebo , cognitive decline , clinical endpoint , clinical trial , biomarker , randomized controlled trial , dementia , pediatrics , psychiatry , pathology , biochemistry , chemistry , alternative medicine , environmental health